We are pleased and honored to introduce Bia Labate, PhD, to the Soltara advisory team as Science and Culture Coordinator.
08:43 min
CLEAR ALL
Once considered the quintessential party drug, MDMA (also known as “ecstasy,” “X,” or “molly”) is now experiencing a surge of interest in a completely different area: psychedelic-assisted psychotherapy.
Like most people of color in the United States, psychotherapist and researcher Monnica Williams has experienced myriad forms of racism. Early in her career, understanding its effects on her mind and body motivated her to help clients address their own racial trauma in therapy.
In the last two decades, researchers have started to reexamine psychedelics for their therapeutic potential. Though initial results seem promising, the research has a significant shortcoming: the lack of racial and ethnic diversity among research teams and study participants.
1
A new study finds widespread exclusion of minorities in psychedelic research.
We’re seeing an explosion of medical research into psychedelics. Psilocybin, or shrooms, to treat major depressive disorder. Ayahuasca, a psychotropic plant medicine from the Amazon, and ibogaine, a potent hallucinogen from Africa, to treat addiction. LSD for anxiety.
These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.
2
A recent study found that even a single positive psychedelic experience may ease mental health symptoms associated with racial trauma experienced by Black, Indigenous, and people of color (BIPOC).
Badass women making waves in the psychedelic movement, from research to drug policy reform.
Though researchers are still trying to understand the cognitive and therapeutic mechanics of psychedelics, they have concluded that psilocybin, DMT and other psychoactive chemicals can help people feel more tolerance, understanding and empathy.
The exuberant “renaissance” of studies researching psychedelic-assisted psychotherapy in the past twenty years has not sufficiently included the enrollment of racially diverse participants, a problem that psychedelic science and clinical research shares with mainstream psychiatry